Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells (Q40590517)

21 September 2017

Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells (English)

1 reference

21 September 2017

Darrin M Beaupre

1

1 reference

21 September 2017

Jennifer McCafferty-Grad

2

1 reference

21 September 2017

Nizar J Bahlis

3

1 reference

21 September 2017

Lawrence H Boise

4

1 reference

21 September 2017

Mathias G Lichtenheld

5

1 reference

21 September 2017

1 December 2003

1 reference

21 September 2017

1 reference

21 September 2017

44

1 reference

21 September 2017

12

1 reference

21 September 2017

2123-2134

1 reference

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

21 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Expression of Bcl-2 family of proteins in fresh myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

PI3K: downstream AKTion blocks apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

The AKT kinase is activated in multiple myeloma tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Regulation of cell death protease caspase-9 by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

The biochemistry of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Death receptors: signaling and modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Cell cycle: routine role for Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Effect of a dominant inhibitory Ha-ras mutation on mitogenic signal transduction in NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Cell cycle targets of Ras/Raf signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Signaling pathways activated by daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Fas antigen/APO-1 (CD95) expression on myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1042819031000116652

10.1080/1042819031000116652

21 January 2018

Identifiers

DOI

1 reference

21 September 2017

1 reference